Amyloid beta biosensors in neurodegenerative disease.

The accumulation of amyloid beta (Aβ) peptides in the brain is a hallmark of several neurodegenerative diseases, particularly Alzheimer's disease. Early and accurate detection of Aβ is crucial for timely intervention and effective management of these conditions. This paper explores the role of biosensors in detecting amyloid beta, highlighting recent advancements in sensor technology that enhance sensitivity, specificity, and real-time monitoring capabilities. We discuss various biosensor platforms, including electrochemical, optical, and nanomaterial-based sensors, and their applications in both research and clinical settings. Furthermore, we examine the challenges faced in the development and implementation of these biosensors, such as biocompatibility, integration with existing diagnostic tools, and regulatory considerations. By providing a comprehensive overview of the current state of biosensor technology for Aβ detection, this study aims to underscore the potential of these innovative tools in improving neurodegenerative disease management and facilitating the development of targeted therapeutic strategies.